SCHEMBL4862477

SCHEMBL4862477

C[C@@H](O)c1cnc(-c2ccc(C(F)(F)F)cc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.43
PRMT5 O14744 1/20 0.40
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
PPARD Q03181 2/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CRHBP P24387 1/20 0.38
KMT2A Q03164 1/20 0.38
CRHR2 Q13324 1/20 0.38
DYRK1A Q13627 2/20 0.37
DYRK2 Q92630 2/20 0.37
CDK2 P24941 2/20 0.37
DYRK3 O43781 1/20 0.37
CCNA2 P20248 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
TRPV3 Q8NET8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3375383 1.00 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL4862481 1.00 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL23367934 0.88 PDE2A (0.44) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL27650502 0.85 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL4860740 0.85 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL4860735 0.85 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL27769540 0.84 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL14814605 0.83 PTPN11 (0.42) NPC1ALDH1A1MAPTKDM4EMEN1
SCHEMBL27769542 0.81 PDE2A (0.43) PDE2APRMT5NPC1ALDH1A1GAA
SCHEMBL608076 0.80 SMN1; SMN2 (0.49) NPC1ALDH1A1GAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG PDE2A 718/4885PRMT5 1321/4885NPC1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.